Effectiveness of cyclosporine A in patients with moderate to severe plaque psoriasis in a real-life clinical setting in Italy: the TRANSITION study

Figures & data

Figure 1. TRANSITION study design. CsA: Cyclosporine A.

Table 1. Demographics and baseline characteristics.

Variable	CsA, N = 196
Age (yrs), mean (SD)	46.59 (15.36)
Male, n (%)	123 (62.8)
Caucasian, n (%)	189 (96.4)
Height (cm), mean (SD) [n = 169]	170.78 (9.18)
Weight (kg), mean (SD) [n = 173]	75.67 (15.28)
BMI (kg/m^2), mean (SD) [n = 169]	25.84 (4.39)
Waist (cm), mean (SD) [n = 167]	93.59 (14.55)
SBP (mm Hg), mean (SD) [n = 189]	125.05 (12.20)
DBP (mm Hg), mean (SD) [n = 189]	77.53 (8.91)
Pulse (bpm), mean (SD) [n = 168]	70.93 (8.03)
Smoking status, n (%)
Never	125 (63.8)
Current	54 (27.6)
Former	17 (8.7)
Disease duration (yrs), mean (SD)	14.26 (12.16)

Percentages are based on N. BMI: body mass index; CsA: cyclosporine A; DBP diastolic blood pressure; N: number of evaluable patients; n: number of patients who satisfied the criteria; SBP: systolic blood pressure; SD: standard deviation.

Table 2. Medical history: current medical condition of patients.

Most frequent (>2%) condition by PT, n (%)	CsA, N = 196
Any condition	89 (45.4)
Hypertension	40 (20.4)
Psoriatic arthropathy	7 (3.6)
Hypercholesterolaemia	7 (3.6)
Hypothyroidism	5 (2.6)
Diabetes mellitus	5 (2.6)
Dyslipidaemia	5 (2.6)
Hyperuricaemia	5 (2.6)

CsA: cyclosporine A; N: number of evaluable patients; n: number of patients who satisfied the criteria; PT: preferred term.

Table 3. Reasons for permanent discontinuation from the last CsA cycle.

Reason for discontinuation, n (%)	CsA, N = 196
Number of patients who permanently discontinued	56 (28.6)
Reason for permanent discontinuation
Poor tolerability	7 (3.6)
Lack of efficacy	20 (10.2)
Voluntary discontinuation by patient	7 (3.6)
Other	23 (11.7)

More than one reason per patient could be selected. CsA: cyclosporine A; N: number of evaluable patients; n: number of patients who satisfied the criteria.

Figure 2. Percentage of partial- and suboptimal-responder patients. Non-responder: PASI response <50%; Partial Responder: PASI response is between 50% and <75%; Suboptimal Responder: PASI response is between 75% and <90%; Responder: PASI response ≥90%; N: number of evaluable patients; n: number of patients who satisfied the criteria; PASI: Psoriasis Area and Severity Index.

Figure 3. PASI score over time. CsA, cyclosporine A; ΔPASI, change in Psoriasis Area and Severity Index score between assessments.

Figure 4. Percentage of patients with DLQI 0/1 by PASI response. DLQI: Dermatology Life Quality Index; PASI: Psoriasis Area and Severity Index.

Figure 5. Treatment Satisfaction Questionnaire of Medication. Mean (SD) TSQM Domain scores are reported. SD: standard deviation; TSQM: Treatment Satisfaction Questionnaire of Medication.

Table 4. Correlation between PASI score and each domain of TSQM, using the Spearman correlation coefficient.

PASI score versus TSQM	CsA, N = 196 (Spearman correlation coefficient (p-value))
Effectiveness	–0.5364 (<.0001)
Convenience	–0.2162 (.0023)
Global Satisfaction	–0.5453 (<.0001)
Side effects	–0.1068 (.1362)

CsA: Cyclosporine A; N: number of evaluable patients.